Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.
Meegalla, S.K., Huang, H., Illig, C.R., Parks, D.J., Chen, J., Lee, Y.K., Wilson, K.J., Patel, S.K., Cheung, W.S., Lu, T., Kirchner, T., Askari, H.B., Geisler, J., Patch, R.J., Gibbs, A.C., Rady, B., Connelly, M., Player, M.R.(2016) Bioorg Med Chem Lett 26: 4216-4222
- PubMed: 27491708
- DOI: https://doi.org/10.1016/j.bmcl.2016.07.054
- Primary Citation of Related Structures:
5K9R - PubMed Abstract:
Design and optimization of a novel series of imidazo[1,2-b]pyridazine PDE10a inhibitors are described. Compound 31 displays excellent pharmacokinetic properties and was also evaluated as an insulin secretagogue in vitro and in vivo.
Organizational Affiliation:
Janssen Research & Development, Welsh and McKean Roads, Spring House, PA 19477-0776, USA.